IONS Ionis Pharmaceuticals, Inc.

The latest trades reveal where Wood sees opportunity

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN). "These interim phase 3 results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function in people with IgA nephropathy’’ said Levi Garraway, Roche’s Chief Medical Officer and Head of Glo

ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.

Ark Invest added nearly $25 million of CoreWeave as it trimmed several major AI and technology holdings

Shares of Ionis are down more than 40% so far this year.

Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies. Monia said the company has secured two

Ionis Pharmaceuticals (IONS) is back in focus after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen failed to reduce major cardiovascular events despite sharply lowering Lp(a) levels. The pelacarsen setback comes after a sharp reset in sentiment. Ionis Pharmaceuticals has posted a 7-day share price return of negative 15.99% and a 30-day share price return of negative 21.59%. Despite this, the company still has a 5-year total shareholder return of 25.67%,...

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients. The drug did lower Lp(a) levels […]

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology medicine. The FDA-approved Zanvastro, chemically known as zilganersen, for adults and children with Alexander disease, has taken the lead as the first approved disease-modifying treatment for the rare neurological disorder. Ionis has set a price of $285,000 per dose […]

Novartis AG’s (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZON study. Bank of America does not believe the result breaks the Novartis (NYSE:NVS) investment thesis. The firm estimates that the failed study creates […]

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]

Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.

Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.

Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death

On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1). The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia. Read Also: A Wall St

Ionis Pharmaceuticals (NASDAQ:IONS) shares fell 13. 1% to $50.

Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.

The U.S. Food and Drug Administration has approved Zanvastro (zilganersen), manufactured by Ionis Pharmaceuticals Inc., for Alexander disease in adult and pediatric patients. Zanvastro becomes the first and only disease-modifying therapy available for this ultra-rare, progressive, and frequently fatal neurological...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.

The company’s shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.

Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.

Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.

Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene. The approval includes a bro

Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.

The U.S. Food and Drug Administration has approved Zanvastro (zilganersen), manufactured by Ionis Pharmaceuticals Inc. (NASDAQ:IONS), for Alexander disease in adult and pediatric patients. Zanvastro becomes the first and only disease-modifying therapy available for this ultra-rare, progressive, and frequently fatal neurological disorder. Prior to this regulatory authorization, clinical care for affected individuals remained strictly limited to symptom management. First Approved Disease-Modifying

Ionis Pharmaceuticals (IONS) just received U.S. FDA approval for ZANVASTRO, an RNA targeted treatment for Alexander disease in pediatric and adult patients. The stock now reflects a new approved rare disease asset. Even with the FDA approval for ZANVASTRO, Ionis Pharmaceuticals shares have been under pressure in the near term, with the 1-day share price return down 5.22% and the 7-day share price return down 6.89%. The 30-day share price return is up 5.56% from a weaker base, and the...

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

The U.S. FDA has approved Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s Zanvastro (zilganersen) as the first FDA-approved treatment for Alexander disease (AxD), a rare, progressive neurological disorder caused by mutations in the GFAP gene. The disease affects fewer than 1,000 people in the U.S. and can lead to seizures, loss of developmental milestones, impaired movement, and other […]

Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On August 20, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that it will present new cardiometabolic data for TRYNGOLZA (olezarsen) and its investigational siRNA ION775 at the European Society of Cardiology (ESC) Congress 2026 in Munich. Following its June U.S. FDA approval for severe hypertriglyceridemia (sHTG), the spotlight centers on 1-year Phase 3 extension data showing sustained […]

Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares trading at a premium rather than as an obvious bargain. Ionis Pharmaceuticals has delivered a 47.3% return over the past three years, which puts recent pricing in focus for anyone considering new capital at work. The recent securities investigation following the Wainua trial setback may weigh on risk perceptions, while any renewed...